VSTM News and Press, Verastem Inc. From 03/01/26

2026-03-01 08:07:29 ET More on related stocks: Buy CrowdStrike As Trust Is Key In The Age Of AI Agents Costco's 2x P/E Over Amazon Is Not Irrational (Rating Upgrade) Broadcom Q1 Preview: Tech Rotation Could Trigger Another Irrational Selloff Costco is called ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and bus...

2026-02-04 08:11:31 ET Read the full article on Seeking Alpha For further details see: Verastem posts preliminary 2025 revenue, plans clinical updates in 2026

Based on preliminary, unaudited results, Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million for the full year 2025, following U.S. FDA approval in May 2025 1 Compa...

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com  News Commentary VANCOUVER, BC , Jan. 30, 2026 /CNW/ -- The global oncology sector is rocketing toward $668 bi...

2026-01-08 17:45:37 ET The last time I spoke about Immuneering Corporation ( IMRX ) it was in a Seeking Alpha article entitled "Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst." With respect to this article, I mentioned that this company was a...

2026-01-07 16:59:39 ET More on Immuneering Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 Immuneering Corporation 2025 Q3 - Results - Earnings Call Presentation Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript Immuneering to...

2025-12-30 15:37:25 ET The last time I wrote about Verastem, Inc. ( VSTM ) it was in a Seeking Alpha article entitled "Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination." With respect to this article, I highlighted the opportunity that this company had ...

2025-12-29 16:50:30 ET More on Verastem Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript Verastem, Inc. 2025 Q3 - Results - Earnings Call Presentation Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade) Verastem Oncology...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer...